CL2023002705A1 - Nuevos derivados de tiazolopirimidinona - Google Patents
Nuevos derivados de tiazolopirimidinonaInfo
- Publication number
- CL2023002705A1 CL2023002705A1 CL2023002705A CL2023002705A CL2023002705A1 CL 2023002705 A1 CL2023002705 A1 CL 2023002705A1 CL 2023002705 A CL2023002705 A CL 2023002705A CL 2023002705 A CL2023002705 A CL 2023002705A CL 2023002705 A1 CL2023002705 A1 CL 2023002705A1
- Authority
- CL
- Chile
- Prior art keywords
- new
- thiazolopyrimidinone
- derivatives
- thiazolopyrimidinone derivatives
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La invención se refiere a un compuesto de fórmula (I); en el que R1-R4 y A1-A3 son como se definen en la descripción y en las reivindicaciones. El compuesto de fórmula (I) se puede usar como un medicamento.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21163259 | 2021-03-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2023002705A1 true CL2023002705A1 (es) | 2024-03-15 |
Family
ID=74947249
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2023002705A CL2023002705A1 (es) | 2021-03-17 | 2023-09-11 | Nuevos derivados de tiazolopirimidinona |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20240018163A1 (es) |
| EP (1) | EP4308576B1 (es) |
| JP (1) | JP2024514421A (es) |
| KR (1) | KR20230157367A (es) |
| CN (1) | CN116981674A (es) |
| AU (1) | AU2022240935A1 (es) |
| BR (1) | BR112023018466A2 (es) |
| CA (1) | CA3212341A1 (es) |
| CL (1) | CL2023002705A1 (es) |
| CO (1) | CO2023012574A2 (es) |
| CR (1) | CR20230437A (es) |
| IL (1) | IL305203A (es) |
| MX (1) | MX2023010719A (es) |
| PE (1) | PE20241189A1 (es) |
| TW (1) | TW202302604A (es) |
| WO (1) | WO2022194801A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112022020418A2 (pt) * | 2020-04-08 | 2023-05-02 | Remix Therapeutics Inc | Compostos e métodos para modulação de splicing |
| WO2023064879A1 (en) * | 2021-10-13 | 2023-04-20 | Remix Therapeutics Inc. | Compounds and methods for modulating nucleic acid splicing |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119528903A (zh) | 2012-02-10 | 2025-02-28 | Ptc医疗公司 | 用于治疗脊髓性肌萎缩的化合物 |
| PL3663296T3 (pl) | 2014-05-15 | 2023-08-07 | F. Hoffmann-La Roche Ag | Sposób wytwarzania związków użytecznych w leczeniu rdzeniowego zaniku mięśni |
| KR20200033249A (ko) * | 2017-06-05 | 2020-03-27 | 피티씨 테라퓨틱스, 인크. | 헌팅턴병 치료 화합물 |
| CA3067591A1 (en) * | 2017-06-28 | 2019-01-03 | Ptc Therapeutics, Inc. | Methods for treating huntington's disease |
| MX2020002711A (es) | 2017-09-22 | 2020-07-20 | Hoffmann La Roche | Proceso para preparacion de 7-(4,7-diazaespiro[2.5]octan-7-il)-2-( 2,8-dimetilimidazo[1,2-b]piridazin-6-il)pirido[1,2-a]pirimidin-4- ona. |
| EP3814360B8 (en) * | 2018-06-27 | 2024-11-06 | PTC Therapeutics, Inc. | Heteroaryl compounds for treating huntington's disease |
| EA202092899A1 (ru) * | 2018-06-27 | 2021-05-14 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | Гетероарильные соединения для лечения болезни гентингтона |
| BR112022020418A2 (pt) * | 2020-04-08 | 2023-05-02 | Remix Therapeutics Inc | Compostos e métodos para modulação de splicing |
-
2022
- 2022-03-15 KR KR1020237032218A patent/KR20230157367A/ko active Pending
- 2022-03-15 EP EP22714821.0A patent/EP4308576B1/en active Active
- 2022-03-15 PE PE2023002576A patent/PE20241189A1/es unknown
- 2022-03-15 CA CA3212341A patent/CA3212341A1/en active Pending
- 2022-03-15 MX MX2023010719A patent/MX2023010719A/es unknown
- 2022-03-15 JP JP2023556976A patent/JP2024514421A/ja active Pending
- 2022-03-15 CN CN202280021604.7A patent/CN116981674A/zh active Pending
- 2022-03-15 CR CR20230437A patent/CR20230437A/es unknown
- 2022-03-15 IL IL305203A patent/IL305203A/en unknown
- 2022-03-15 AU AU2022240935A patent/AU2022240935A1/en active Pending
- 2022-03-15 BR BR112023018466A patent/BR112023018466A2/pt not_active Application Discontinuation
- 2022-03-15 WO PCT/EP2022/056586 patent/WO2022194801A1/en not_active Ceased
- 2022-03-16 TW TW111109552A patent/TW202302604A/zh unknown
-
2023
- 2023-09-11 CL CL2023002705A patent/CL2023002705A1/es unknown
- 2023-09-15 US US18/468,378 patent/US20240018163A1/en active Pending
- 2023-09-22 CO CONC2023/0012574A patent/CO2023012574A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022194801A1 (en) | 2022-09-22 |
| BR112023018466A2 (pt) | 2023-10-10 |
| CN116981674A (zh) | 2023-10-31 |
| PE20241189A1 (es) | 2024-06-03 |
| CA3212341A1 (en) | 2022-09-22 |
| AU2022240935A1 (en) | 2023-08-24 |
| EP4308576A1 (en) | 2024-01-24 |
| IL305203A (en) | 2023-10-01 |
| MX2023010719A (es) | 2023-09-20 |
| EP4308576C0 (en) | 2025-04-23 |
| CO2023012574A2 (es) | 2023-09-29 |
| TW202302604A (zh) | 2023-01-16 |
| KR20230157367A (ko) | 2023-11-16 |
| JP2024514421A (ja) | 2024-04-02 |
| EP4308576B1 (en) | 2025-04-23 |
| US20240018163A1 (en) | 2024-01-18 |
| CR20230437A (es) | 2023-10-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2022007621A2 (es) | Nuevos inhibidores de braf como rompedores de la paradoja | |
| CL2023002705A1 (es) | Nuevos derivados de tiazolopirimidinona | |
| MX2021005714A (es) | Nuevos compuestos heterociclicos. | |
| CO2019003178A2 (es) | Compuestos de dinucleótidos cíclicos | |
| CO2023004195A2 (es) | Compuestos heterocíclicos | |
| CO2023014721A2 (es) | Compuestos heterocíclicos | |
| CL2020003331A1 (es) | Nuevos compuestos de piridina y pirazina como inhibidores del receptor cannabinoide 2 | |
| MX2020007565A (es) | Nuevos oxadiazoles. | |
| CR20160459A (es) | Nuevos derivados de piridina | |
| BR112018011562A2 (pt) | novos derivados de fenil | |
| MX2023013721A (es) | Nuevas piridinas sustituidas como fungicidas. | |
| CR20160448A (es) | Nuevos derivados de piridina | |
| CO2018011231A2 (es) | Derivados de [1,2,3]triazolo[4,5-d]pirimidina con afinidad por los receptores canabinoides tipo-2 | |
| CL2020003248A1 (es) | Derivados de tetrahidrotienopiridina n-sustituidos y sus usos | |
| BR112021026899A2 (pt) | Compostos heterocíclicos | |
| CO2024001125A2 (es) | (3-piridil)-quinazolina | |
| CL2023003921A1 (es) | Inhibidores de transglutaminasas | |
| CO2023015524A2 (es) | Nuevas piridinas sustituidas como fungicidas | |
| CO2023008475A2 (es) | Inhibidores de enzimas | |
| AR126383A1 (es) | Combinaciones insecticidas que comprenden un compuesto de antranilamida y tau-fluvalinato | |
| MX2024001592A (es) | (3-quinolil)-quinazolina. | |
| CO2018007756A2 (es) | Nuevos derivados pirrolidina | |
| MX2023004955A (es) | Compuestos de aminotiazol deuterados como compuestos antiviricos. | |
| AR132478A1 (es) | Nuevos derivados de tieno[3,2-b]piridina | |
| CO2024010453A2 (es) | Nuevos derivados de benzimidazol piridina |